FDA-approved CAR-T cell therapies
| Name | Target antigen | Disease | Year of approval |
|---|---|---|---|
| Tisagenlecleucel (Kymriah) | CD19 | B-ALL, NHL | 2017 |
| Axicabtagene ciloleucel (Yescarta) | CD19 | NHL, follicular lymphoma | 2017 |
| Brexucabtagene autoleucel (Tecartus) | CD19 | MCL, B-ALL | 2021 |
| Lisocabtagene maraleucel (Breyanzi) | CD19 | NHL | 2021 |
| Idecabtagene vicleucel (Abecma) | BCMA | Multiple myeloma | 2021 |
| Ciltacabtagene autoleucel (Carvykti) | BCMA | Multiple myeloma | 2022 |
B-ALL: B cell acute lymphoblastic leukemia; NHL: non-Hodgkin lymphoma; MCL: mantle cell lymphoma